Supriya Lifescience Ltd.

NSE: SUPRIYA | BSE: 543434 | ISIN: INE07RO01027 | Industry: Pharmaceuticals
| Expensive Performer
667.8500 22.00 (3.41%)
NSE Mar 21, 2025 11:18 AM
Volume: 149.4K
 

667.85
3.41%
KRChoksey
For Q2FY24, Supriya Lifescience's revenue grew 24.9% YoY and 6.1% QoQ to INR 1,401 Mn, while for H1FY24, revenue grew 27.4% YoY to 2,721 Mn. In terms of revenue break up, analgesic/anti-pyretic/anesthetic (56.0% share in Q2FY24) grew by 29.9% YoY, anti histamine (2.0% share in Q2FY24) grew by 21.8% YoY, vitamin (11.0% share in Q2FY24) grew by 26.3% YoY, anti-asthma (10.0% share in Q2FY24) grew by 26.2% YoY, anti-allergic (8.0% share in Q2FY24) grew by 31.9% YoY, anti-malarial (2.0% share in Q2FY24) grew by 3.8% YoY, and others (11.0% share in Q2FY24) grew by 3.4% YoY.
Number of FII/FPI investors increased from 69 to 85 in Dec 2024 qtr.
More from Supriya Lifescience Ltd.
Recommended